

Biohit Oyj

Company report

12/20/2023



Antti Siltanen
+358 45 119 6869
antti.siltanen@inderes.fi

✓ Inderes corporate customer

This report is a summary translation of the report “Perusasioiden kautta kasvumoodiin” published on 12/20/2023 at 7:30 am EET.

inde
res.

From basics to growth mode

We reiterate our Accumulate recommendation for Biohit and revise our target price to EUR 2.3 (was 2.4) due to updated forecasts. In its recent strategy update for 2024-2028, Biohit said it aims to achieve 15-20% annual growth with an EBIT target of at least 10% of revenue. Compared to our previous forecasts, the targets emphasize growth, with profitability taking a back seat. We have updated our forecasts to higher growth, but contrastively we have slightly lowered our earnings expectations. With capital geared towards supporting growth, we no longer expect dividends in the coming years. The valuation picture has remained largely unchanged, and the risk/return ratio of the stock remains attractive.

The strategy focuses on growth

Over the past two years or so, Biohit has focused particularly on improving operational efficiency, which we estimate has already been reflected in the reported figures. With the new 2024-2028 strategy, improving efficiency seems to have become part of Biohit's daily business and the company's focus is shifting towards longer-term growth. The strategy's annual growth target of 15-20% is ambitious compared to the projected growth of around 4.5% in the gastrointestinal diagnostics market, but we believe it is achievable. According to a recent interview with the CEO, the focus is on organic growth, which can be complemented by acquisitions where necessary and possible. The pursuit of rapid growth is reflected in an EBIT target of more than 10% of revenue, which is modest compared to the potential. Biohit already reached this level in 2022, so now the focus is clearly on revenue growth.

Estimate revisions reflect the targets of the strategy

We are raising our revenue forecasts for 2024-2025 by 4-9%, in line with the company's more growth-oriented strategy. We are keeping our growth forecasts for the rest of 2023 unchanged. We expect annual growth of 8-14% over the whole strategy period. Our forecast is slightly below the company's targets and based on our estimate of organic growth. We have not included possible inorganic growth in our projections because of the difficulty of forecasting it. In practice, our forecast expects Biohit to grow 2-3 times faster than the market (~4.5%) over the strategy period. Our EBIT forecasts for 2024-2025 are down 10-15%. We expect the pursuit of growth to be reflected in faster cost increases than our previous forecasts, which will be reflected in slightly lower profitability. We expect the EBIT margin to gradually improve over the strategy period and reach 15% of revenue by the end of the strategy period in 2028. This represents our view of Biohit's medium-term earnings potential. In a slower growth environment, we see opportunities to further improve profitability (terminal growth of 2.5% and EBIT of 20%). Despite a strong balance sheet, we no longer expect dividends in the coming years as growth requires capital.

Valuation picture remains attractive

The EV/EBIT multiples for 2024-2025 are 12x and 9x, which we consider attractive given the company's growth prospects and profitability potential. The 2024 median multiple for the peer group that merits a higher valuation is 20x. The 2024-2025 EV/S multiples of 1.5x-1.3x are low compared to the company's own history and peers. The DCF model also indicates a moderate upside for the share.

Recommendation

Accumulate


(previous Accumulate)

EUR 2.30

(previous EUR 2.40)

Share price:

1.92



Key figures

	2022	2023e	2024e	2025e
Revenue	11.0	12.4	14.1	16.0
growth-%	17%	13%	14%	14%
EBIT adj.	1.1	1.9	1.9	2.4
EBIT-% adj.	10.3 %	15.4 %	13.1 %	14.7 %
Net Income	0.6	1.7	1.7	1.9
EPS (adj.)	0.04	0.11	0.11	0.12

P/E (adj.)	39.3	18.1	17.5	15.4
P/B	3.1	3.2	2.7	2.3
Dividend yield-%	0.0 %	0.0 %	0.0 %	0.0 %
EV/EBIT (adj.)	16.3	12.0	11.7	8.6
EV/EBITDA	11.4	9.7	9.4	7.1
EV/S	1.7	1.8	1.5	1.3


Source: Inderes

Guidance

(Revised)


Biohit expects revenue to be EUR 12-13 million in 2023 (2022: EUR 11 million) and our EBIT to increase compared to 2022 (in 2022: 1.1 MEUR).

Share price




Source: Millistream Market Data AB

Revenue and EBIT-%



Source: Inderes

EPS and dividend



Source: Inderes



Value drivers

- Growth in new GastroPanel® products
- Increased operational efficiency
- Renewed distribution agreement in China
- Using the strong balance sheet to pay dividends or to create opportunities for inorganic growth



Risk factors

- Dependency on the Chinese market
- Small resources relative to competitors
- Failure in developing new products
- The aging of the current product portfolio and its loss of competitiveness
- Poor visibility of estimates

Valuation	2023e	2024e	2025e
Share price	1.92	1.92	1.92
Number of shares, millions	15.1	15.1	15.1
Market cap	29	29	29
EV	23	22	20
P/E (adj.)	18.1	17.5	15.4
P/E	18.1	17.5	15.4
P/FCF	36.5	26.5	21.2
P/B	3.2	2.7	2.3
P/S	2.3	2.1	1.8
EV/Sales	1.8	1.5	1.3
EV/EBITDA	9.7	9.4	7.1
EV/EBIT (adj.)	12.0	11.7	8.6
Payout ratio (%)	0.0 %	0.0 %	0.0 %
Dividend yield-%	0.0 %	0.0 %	0.0 %

Source: Inderes

Growth first, profitability second

Estimate revisions 2023e-2025e

- We keep our estimates unchanged for the rest of 2023.
- We are raising our revenue forecasts by 4-9% for 2024-2025, in line with the updated strategy.
- The impact of the growth-oriented strategy is also reflected in our forecasts for the whole strategy period, which we have raised moderately.
- Our EBIT forecasts decline moderately by 10-15% between 2024 and 2025. The revision is based on rising costs due to increased growth forecasts, which are weighing on profitability.
- We have also revised our longer-term profitability forecasts moderately downwards.
- Despite the strong balance sheet, we no longer expect dividends in the coming years. In our view, organic growth and maintaining the M&A opportunity will require capital, which we believe Biohit will protect by refraining from paying a dividend.

Estimate revisions MEUR / EUR	2023e		Change	2024e		Change	2025e		Change
	Old	New	%	Old	New	%	Old	New	%
Revenue	12.4	12.4	0%	13.6	14.1	4%	14.8	16.0	8%
EBITDA	2.4	2.4	0%	2.6	2.3	-12%	3.1	2.9	-8%
EBIT (exc. NRIs)	1.9	1.9	0%	2.2	1.9	-15%	2.6	2.4	-10%
EBIT	1.9	1.9	0%	2.2	1.9	-15%	2.6	2.4	-10%
PTP	1.9	1.9	0%	2.2	1.9	-15%	2.6	2.4	-10%
EPS (excl. NRIs)	0.11	0.11	0%	0.13	0.11	-16%	0.14	0.12	-10%
DPS	0.00	0.00		0.05	0.00	-100%	0.06	0.00	-100%

Source: Inderes

Valuation still attractive

Earnings multiples are moderate considering growth and profitability potential

Biohit's P/E ratios are 18x and 15x (previously 20x and 16x) for 2024-2025. However, we believe that the company's valuation is better described by the EV/EBIT ratio that considers the large net cash, and that is 12x for 2023 and 9x for 2024 (previously 14x and 11x). The median multiple for the peer group is 20x. Earnings multiples continue to fall in the coming years, although the lack of visibility means that the reliability of the estimates suffer when assessing the longer term. Therefore, we rely mainly on 2024-2025 multiples in our examination. We find the multiples attractive considering the growth rate we expect, defensive demand, and the medium-term potential for improving profitability. The profitability potential is indicated by the EBIT margin of mature diagnostic companies in 2022 of 17.1% (Bloomberg Global In Vitro Diagnostic Competitors Index companies). The company's own historical earnings multiples cannot be compared because of the loss-making business.

On revenue basis, the share is cheap compared to history and the peers

Biohit's revenue-based EV/S ratio for 2023 is 1.5x (previously 1.6x) and will decrease to 1.3x in 2025 (previously 1.6x). The ratios are well below the company's own recent history with the median for 2018-2022 being 3.6x. Pricing relative to the company's own history is favorable, especially in view of the current turnaround. The median multiples for Biohit's peers is 3.7x for 2024.

Cash flow calculation indicates a reasonable upside


The DCF model gives a present value of future cash flows per share of EUR 2.3 (was 2.4), suggesting a reasonable upside potential to the current share price. Our terminal growth assumption is 2.5%, based on the growth outlook of the health care needs of the aging population. For the terminal, we assume an EBIT margin of 20%, driven by the industry's mature companies and Biohit's high sales margin. We have used a weighted average cost of capital (WACC) of 10.5%. WACC is elevated by the risks related to the materialization of the estimates and the aging product portfolio. On the downside, the strong balance sheet, evidence of a turnaround in earnings and the defensive nature of the industry and its good profitability potential lower the WACC.

Valuation summary

Our view on the fair value of Biohit's share is EUR 1.7-3.0, which corresponds to a 2024 EV/EBIT range of 10x-21x and an EV/S range of 1.3x-2.7x. Earnings and revenue multiples play a key role in our view, and they indicate that the share is modestly valued relative to earnings and revenue growth. We feel that the discount to the peers and the company's own history is relatively high, although the peer group we use does not correspond particularly well with Biohit. The DCF model also indicates an upside in the share and meets our required return.

Valuation	2023e	2024e	2025e
Share price	1.92	1.92	1.92
Number of shares, millions	15.1	15.1	15.1
Market cap	29	29	29
EV	23	22	20
P/E (adj.)	18.1	17.5	15.4
P/E	18.1	17.5	15.4
P/FCF	36.5	26.5	21.2
P/B	3.2	2.7	2.3
P/S	2.3	2.1	1.8
EV/Sales	1.8	1.5	1.3
EV/EBITDA	9.7	9.4	7.1
EV/EBIT (adj.)	12.0	11.7	8.6
Payout ratio (%)	0.0 %	0.0 %	0.0 %
Dividend yield-%	0.0 %	0.0 %	0.0 %



Source: Inderes



Valuation table

Valuation	2018	2019	2020	2021	2022	2023e	2024e	2025e	2026e
Share price	2.96	3.36	2.48	1.84	1.57	1.92	1.92	1.92	1.92
Number of shares, millions	15.0	15.0	15.0	15.0	15.0	15.1	15.1	15.1	15.1
Market cap	44	51	37	28	24	29	29	29	29
EV	35	42	32	22	18	23	22	20	19
P/E (adj.)	neg.	neg.	neg.	neg.	39.3	18.1	17.5	15.4	13.4
P/E	neg.	neg.	neg.	neg.	39.3	18.1	17.5	15.4	13.4
P/FCF	neg.	neg.	neg.	neg.	42.0	36.5	26.5	21.2	18.9
P/B	2.8	3.4	4.2	3.8	3.1	3.2	2.7	2.3	2.0
P/S	4.5	5.0	5.2	3.0	2.2	2.3	2.1	1.8	1.6
EV/Sales	3.6	4.2	4.4	2.4	1.7	1.8	1.5	1.3	1.0
EV/EBITDA	neg.	70.5	neg.	44.0	11.4	9.7	9.4	7.1	5.3
EV/EBIT (adj.)	neg.	neg.	neg.	neg.	16.3	12.0	11.7	8.6	6.9
Payout ratio (%)	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	20.9 %
Dividend yield-%	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	1.6 %

Source: Inderes



Peer group valuation

Peer group valuation	Market cap	EV	EV/EBIT		EV/EBITDA		EV/S		P/E		Dividend yield-%		P/B
Company	MEUR	MEUR	2023e	2024e	2023e	2024e	2023e	2024e	2023e	2024e	2023e	2024e	2023e
Abbott Laboratories	171877	179852	22.1	21.1	19.2	18.0	4.9	4.7	24.4	23.3	1.9	1.9	4.8
bioMérieux SA	11784	11890	21.2	18.1	14.5	12.8	3.2	3.0	26.9	22.9	0.8	0.8	3.0
Bio Rad Laboratories Inc	8213	7695	21.4	19.8	16.1	15.6	3.1	3.1	26.7	26.2			1.1
Boule Diagnostics AB	36	48	13.2	10.6	8.2	7.1	0.9	0.9	16.5	12.3	1.9	2.7	0.8
DiaSorin SpA	5042	5928	23.7	20.9	15.8	14.5	5.1	4.9	27.7	24.3	1.0	1.1	3.2
Immunovia AB	6		0.1		0.1					0.2			0.5
Qiagen NV	8856	9298	20.4	18.6	15.0	13.9	5.2	4.9	20.6	19.7			2.6
Q-linea AB	29	19					26.4	3.8					0.2
SD Biosensor	994	1003				25.1	2.1	2.0					0.8
Sysmex	10423	10148	20.5	19.8	14.7	13.6	3.8	3.5	32.3	30.8	1.0	1.1	4.2
Exact Sciences Corp	10704	12208			66.4	41.1	5.4	4.7					3.8
OraSure Technologies Inc	517	312	9.8		3.9	34.4	0.8	1.7	14.1				1.4
Biohit Oyj (Inderes)	29	23	12.0	11.7	9.7	9.4	1.8	1.5	18.1	17.5	0.0	0.0	3.2
Average			16.9	18.4	17.4	19.6	7.3	4.9	23.6	20.0	1.3	1.5	2.2
Median			20.5	19.8	14.8	15.0	4.4	3.7	25.5	23.1	1.0	1.1	2.0
Diff-% to median			-42%	-41%	-35%	-37%	-58%	-58%	-29%	-24%	-100%	-100%	61%

Source: Refinitiv / Inderes

Income statement

Income statement	H1'21	H2'21	2021	H1'22	H2'22	2022	H1'23	H2'23e	2023e	H1'24e	H2'24e	2024e	2025e	2026e
Revenue	4.0	5.4	9.4	6.1	4.9	11.0	6.5	5.9	12.4	7.3	6.8	14.1	16.0	18.0
EBITDA	-0.2	0.7	0.5	1.5	0.1	1.6	1.8	0.7	2.4	1.4	0.9	2.3	2.9	3.6
Depreciation	-1.0	-1.0	-2.0	-0.2	-0.3	-0.5	-0.3	-0.3	-0.5	-0.2	-0.3	-0.5	-0.5	-0.8
EBIT (excl. NRI)	-1.2	-0.3	-1.5	1.3	-0.2	1.1	1.5	0.4	1.9	1.2	0.7	1.9	2.4	2.7
EBIT	-1.2	-0.3	-1.5	1.3	-0.2	1.1	1.5	0.4	1.9	1.2	0.7	1.9	2.4	2.7
Net financial items	0.0	0.2	0.2	-0.2	-0.1	-0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
PTP	-1.2	-0.1	-1.3	1.1	-0.2	0.9	1.5	0.4	1.9	1.2	0.7	1.9	2.4	2.7
Taxes	0.0	-0.2	-0.2	-0.2	-0.1	-0.3	-0.1	-0.1	-0.2	-0.1	-0.1	-0.2	-0.5	-0.5
Net earnings	-1.2	-0.3	-1.5	0.9	-0.3	0.6	1.4	0.3	1.7	1.1	0.6	1.7	1.9	2.2
EPS (rep.)	-0.08	-0.02	-0.10	0.06	-0.02	0.04	0.09	0.02	0.11	0.07	0.04	0.11	0.12	0.14

Key figures	H1'21	H2'21	2021	H1'22	H2'22	2022	H1'23	H2'23e	2023e	H1'24e	H2'24e	2024e	2025e	2026e
Revenue growth-%		-24.7 %	31.4 %	52.5 %	-9.5 %	17.0 %	6.6 %	21.6 %	13.2 %	13.0 %	15.0 %	14.0 %	13.5 %	12.5 %
Adjusted EBIT growth-%		-91.2 %	-53.4 %	-208.3 %	-38.6 %	-176.2 %	15.4 %	-335.5 %	68.9 %	-19.8 %	60.7 %	-2.7 %	27.3 %	14.8 %
EBITDA-%	-5.0 %	13.2 %	5.4 %	24.6 %	2.2 %	14.7 %	26.9 %	11.1 %	19.4 %	19.1 %	13.3 %	16.3 %	17.9 %	19.7 %
Adjusted EBIT-%	-30.0 %	-5.2 %	-15.8 %	21.3 %	-3.5 %	10.3 %	23.1 %	6.9 %	15.4 %	16.4 %	9.6 %	13.1 %	14.7 %	15.0 %
Net earnings-%	-30.0 %	-5.6 %	-16.0 %	14.8 %	-6.2 %	5.5 %	21.5 %	5.2 %	13.8 %	15.0 %	8.1 %	11.7 %	11.8 %	12.0 %

Source: Inderes

Balance sheet

Assets	2021	2022	2023e	2024e	2025e
Non-current assets	0.6	1.1	1.3	1.9	2.5
Goodwill	0.0	0.0	0.0	0.0	0.0
Intangible assets	0.1	0.0	0.1	0.5	1.0
Tangible assets	0.4	1.0	1.2	1.4	1.4
Associated companies	0.0	0.0	0.0	0.0	0.0
Other investments	0.1	0.1	0.1	0.1	0.1
Other non-current assets	0.0	0.0	0.0	0.0	0.0
Deferred tax assets	0.0	0.0	0.0	0.0	0.0
Current assets	9.0	9.9	11.2	12.5	14.1
Inventories	0.8	0.9	1.0	1.1	1.1
Other current assets	0.0	0.0	0.0	0.0	0.0
Receivables	2.7	2.8	3.0	3.1	3.2
Cash and equivalents	5.5	6.2	7.2	8.3	9.8
Balance sheet total	9.6	11.0	12.5	14.4	16.5


Source: Inderes

Liabilities & equity	2021	2022	2023e	2024e	2025e
Equity	7.4	7.6	9.2	10.8	12.7
Share capital	2.4	2.4	2.4	2.4	2.4
Retained earnings	1.0	1.8	3.4	5.0	6.9
Hybrid bonds	0.0	0.0	0.0	0.0	0.0
Revaluation reserve	-1.1	-1.7	-1.7	-1.7	-1.7
Other equity	5.1	5.1	5.1	5.1	5.1
Minorities	0.0	0.0	0.0	0.0	0.0
Non-current liabilities	0.1	0.6	0.6	0.6	0.7
Deferred tax liabilities	0.0	0.0	0.0	0.0	0.0
Provisions	-0.1	-0.1	-0.1	-0.1	-0.1
Interest bearing debt	0.2	0.7	0.7	0.7	0.8
Convertibles	0.0	0.0	0.0	0.0	0.0
Other long term liabilities	0.0	0.0	0.0	0.0	0.0
Current liabilities	2.1	2.9	2.7	2.9	3.2
Interest bearing debt	0.0	0.3	0.3	0.3	0.3
Payables	2.1	2.6	2.5	2.7	2.9
Other current liabilities	0.0	0.0	0.0	0.0	0.0
Balance sheet total	9.6	11.0	12.5	14.4	16.5

DCF calculation

DCF model	2022	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	TERM
Revenue growth-%	17.0 %	13.2 %	14.0 %	13.5 %	12.5 %	10.0 %	8.0 %	7.0 %	5.0 %	3.0 %	2.5 %	2.5 %
EBIT-%	10.3 %	15.4 %	13.1 %	14.7 %	15.0 %	14.0 %	15.0 %	17.0 %	18.0 %	19.0 %	19.0 %	19.0 %
EBIT (operating profit)	1.1	1.9	1.9	2.4	2.7	2.8	3.2	3.9	4.3	4.7	4.8	
+ Depreciation	0.5	0.5	0.5	0.5	0.8	1.1	1.3	1.2	1.3	1.3	1.4	
- Paid taxes	-0.3	-0.4	-0.2	-0.5	-0.5	-0.6	-0.6	-0.8	-0.9	-0.9	-1.0	
- Tax, financial expenses	-0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
+ Tax, financial income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Change in working capital	0.3	-0.4	0.0	0.0	-0.4	-0.4	-0.4	-0.4	-0.1	-0.1	-0.1	
Operating cash flow	1.6	1.6	2.1	2.4	2.6	2.9	3.4	4.0	4.6	5.0	5.1	
+ Change in other long-term liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Gross CAPEX	-1.0	-0.7	-1.0	-1.1	-1.1	-1.2	-1.2	-1.3	-1.4	-1.4	-1.8	
Free operating cash flow	0.6	0.9	1.1	1.4	1.5	1.7	2.2	2.7	3.2	3.6	3.3	
+/- Other	0.0	-0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
FCFF	0.6	0.8	1.1	1.4	1.5	1.7	2.2	2.7	3.2	3.6	3.3	42.7
Discounted FCFF		0.8	1.0	1.1	1.1	1.2	1.3	1.5	1.6	1.6	1.4	17.4
Sum of FCFF present value		29.9	29.1	28.1	27.0	25.9	24.7	23.4	21.9	20.3	18.7	17.4
Enterprise value DCF		29.9										
- Interest bearing debt		-0.9										
+ Cash and cash equivalents		6.2										
-Minorities		0.0										
-Dividend/capital return		0.0										
Equity value DCF		35.2										
Equity value DCF per share		2.3										

Cash flow distribution



WACC

Tax-% (WACC)	20.0 %
Target debt ratio (D/(D+E))	10.0 %
Cost of debt	6.0 %
Equity Beta	1.60
Market risk premium	4.75%
Liquidity premium	1.00%
Risk free interest rate	2.5 %
Cost of equity	11.1 %
Weighted average cost of capital (WACC)	10.5 %

Source: Inderes

Summary

Income statement	2020	2021	2022	2023e	2024e	Per share data	2020	2021	2022	2023e	2024e
Revenue	7.1	9.4	11.0	12.4	14.1	EPS (reported)	-0.22	-0.10	0.04	0.11	0.11
EBITDA	-1.2	0.5	1.6	2.4	2.3	EPS (adj.)	-0.22	-0.10	0.04	0.11	0.11
EBIT	-3.2	-1.5	1.1	1.9	1.9	OCF / share	0.00	-0.03	0.10	0.11	0.14
PTP	-3.3	-1.3	0.9	2.1	1.9	FCF / share	-0.02	-0.04	0.04	0.05	0.07
Net Income	-3.3	-1.5	0.6	1.6	1.7	Book value / share	0.58	0.49	0.50	0.61	0.72
Extraordinary items	0.0	0.0	0.0	0.0	0.0	Dividend / share	0.00	0.00	0.00	0.00	0.00
Balance sheet	2020	2021	2022	2023e	2024e	Growth and profitability	2020	2021	2022	2023e	2024e
Balance sheet total	10.8	9.6	11.0	12.5	14.4	Revenue growth-%	-29%	31%	17%	13%	14%
Equity capital	8.8	7.4	7.6	9.2	10.8	EBITDA growth-%	-298%	-143%	217%	46%	-2%
Goodwill	0.0	0.0	0.0	0.0	0.0	EBIT (adj.) growth-%	125%	-53%	-176%	69%	-3%
Net debt	-5.7	-5.3	-5.3	-6.2	-7.3	EPS (adj.) growth-%	134%	-55%	-140%	166%	3%
Cash flow	2020	2021	2022	2023e	2024e	EBITDA-%	-16.5 %	5.4 %	14.7 %	19.0 %	16.3 %
EBITDA	-1.2	0.5	1.6	2.4	2.3	EBIT (adj.)-%	-44.6 %	-15.8 %	10.3 %	15.4 %	13.1 %
Change in working capital	1.2	-0.8	0.3	-0.4	0.0	EBIT-%	-44.6 %	-15.8 %	10.3 %	15.4 %	13.1 %
Operating cash flow	0.0	-0.5	1.6	1.6	2.1	ROE-%	-28.3 %	-18.5 %	8.0 %	19.2 %	16.5 %
CAPEX	-0.3	-0.1	-1.0	-0.7	-1.0	ROI-%	-25.9 %	-17.7 %	14.3 %	20.7 %	17.1 %
Free cash flow	-0.3	-0.6	0.6	0.8	1.1	Equity ratio	81.6 %	76.7 %	68.7 %	73.4 %	75.1 %
Valuation multiples	2020	2021	2022	2023e	2024e	Gearing	-64.7 %	-72.4 %	-69.8 %	-68.0 %	-67.8 %
EV/S	4.4	2.4	1.7	1.8	1.5						
EV/EBITDA (adj.)	neg.	44.0	11.4	9.7	9.4						
EV/EBIT (adj.)	neg.	neg.	16.3	12.0	11.7						
P/E (adj.)	neg.	neg.	39.3	18.1	17.5						
P/B	4.2	3.8	3.1	3.2	2.7						
Dividend-%	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %						

Source: Inderes

Disclaimer and recommendation history

The information presented in Inderes reports is obtained from several different public sources that Inderes considers to be reliable. Inderes aims to use reliable and comprehensive information, but Inderes does not guarantee the accuracy of the presented information. Any opinions, estimates and forecasts represent the views of the authors. Inderes is not responsible for the content or accuracy of the presented information. Inderes and its employees are also not responsible for the financial outcomes of investment decisions made based on the reports or any direct or indirect damage caused by the use of the information. The information used in producing the reports may change quickly. Inderes makes no commitment to announcing any potential changes to the presented information and opinions.

The reports produced by Inderes are intended for informational use only. The reports should not be construed as offers or advice to buy, sell or subscribe investment products. Customers should also understand that past performance is not a guarantee of future results. When making investment decisions, customers must base their decisions on their own research and their estimates of the factors that influence the value of the investment and take into account their objectives and financial position and use advisors as necessary. Customers are responsible for their investment decisions and their financial outcomes.

Reports produced by Inderes may not be edited, copied or made available to others in their entirety, or in part, without Inderes' written consent. No part of this report, or the report as a whole, shall be transferred or shared in any form to the United States, Canada or Japan or the citizens of the aforementioned countries. The legislation of other countries may also lay down restrictions pertaining to the distribution of the information contained in this report. Any individuals who may be subject to such restrictions must take said restrictions into account.

Inderes issues target prices for the shares it follows. The recommendation methodology used by Inderes is based on the share's 12-month expected total shareholder return (including the share price and dividends) and takes into account Inderes' view of the risk associated with the expected returns. The recommendation policy consists of four tiers: Sell, Reduce, Accumulate and Buy. As a rule, Inderes' investment recommendations and target prices are reviewed at least 2–4 times per year in connection with the companies' interim reports, but the recommendations and target prices may also be changed at other times depending on the market conditions. The issued recommendations and target prices do not guarantee that the share price will develop in line with the estimate. Inderes primarily uses the following valuation methods in determining target prices and recommendations: Cash flow analysis (DCF), valuation multiples, peer group analysis and sum of parts analysis. The valuation methods and target price criteria used are always company-specific and they may vary significantly depending on the company and (or) industry.

Inderes' recommendation policy is based on the following distribution relative to the 12-month risk-adjusted expected total shareholder return.

Buy	The 12-month risk-adjusted expected shareholder return of the share is very attractive
Accumulate	The 12-month risk-adjusted expected shareholder return of the share is attractive
Reduce	The 12-month risk-adjusted expected shareholder return of the share is weak
Sell	The 12-month risk-adjusted expected shareholder return of the share is very weak

The assessment of the 12-month risk-adjusted expected total shareholder return based on the above-mentioned definitions is company-specific and subjective. Consequently, similar 12-month expected total shareholder returns between different shares may result in different recommendations, and the recommendations and 12-month expected total shareholder returns between different shares should not be compared with each other. The counterpart of the expected total shareholder return is Inderes' view of the risk taken by the investor, which varies considerably between companies and scenarios. Thus, a high expected total shareholder return does not necessarily lead to positive performance when the risks are exceptionally high and, correspondingly, a low expected total shareholder return does not necessarily lead to a negative recommendation if Inderes considers the risks to be moderate.

The analysts who produce Inderes' research and Inderes employees cannot have 1) shareholdings that exceed the threshold of significant financial gain or 2) shareholdings exceeding 1% in any company subject to Inderes' research activities. Inderes Oyj can only own shares in the target companies it follows to the extent shown in the company's model portfolio investing real funds. All of Inderes Oyj's shareholdings are presented in itemised form in the model portfolio. Inderes Oyj does not have other shareholdings in the target companies analysed. The remuneration of the analysts who produce the analysis are not directly or indirectly linked to the issued recommendation or views. Inderes Oyj does not have investment bank operations.

Inderes or its partners whose customer relationships may have a financial impact on Inderes may, in their business operations, seek assignments with various issuers with respect to services provided by Inderes or its partners. Thus, Inderes may be in a direct or indirect contractual relationship with an issuer that is the subject of research activities. Inderes and its partners may provide investor relations services to issuers. The aim of such services is to improve communication between the company and the capital markets. These services include the organisation of investor events, advisory services related to investor relations and the production of investor research reports.

More information about research disclaimers can be found at www.inderes.fi/research-disclaimer.

Inderes has made an agreement with the issuer and target of this report, which entails compiling a research report.

Recommendation history (>12 mo)

Date	Recommendation	Target	Share price
6/30/2023	Accumulate	2.10 €	1.78 €
8/10/2023	Accumulate	2.40 €	2.11 €
12/20/2023	Accumulate	2.30 €	1.92 €



Inderes democratizes investor information by connecting investors and listed companies.

We help over 400 listed companies better serve investors. Our investor community is home to over 70,000 active members.

We build solutions for listed companies that enable frictionless and effective investor relations. For listed companies, we offer Commissioned Research, IR Events, AGMs, and IR Software.

Inderes is listed on the Nasdaq First North growth market and operates in Finland, Sweden, Norway, and Denmark.

Inderes Oyj

Itämerentori 2

FI-00180 Helsinki, Finland

+358 10 219 4690

Award-winning research at [inderes.fi](https://www.inderes.fi)



**STARMINE
ANALYST AWARDS
FROM REFINITIV**



THOMSON REUTERS
ANALYST AWARDS



Juha Kinnunen
2012, 2016, 2017, 2018, 2019, 2020



Mikael Rautanen
2014, 2016, 2017, 2019



Sauli Vilén
2012, 2016, 2018, 2019, 2020



Antti Viljakainen
2014, 2015, 2016, 2018, 2019, 2020



Olli Koponen
2020



Joni Grönqvist
2019, 2020



Erkki Vesola
2018, 2020



Petri Gostowski
2020



Atte Riikola
2020

**Connecting investors
and listed companies.**